{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","name":"Risk-Stratified Stroke Prevention with SGLT2 Inhibitors: A Meta-Analysis of ASCVD-Dependent Efficacy","doi":"10.17605/OSF.IO/T5VXZ","doi_status":"minted","osf_url":"https://osf.io/t5vxz/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_0134cbff36074bf6/chain","content_hash":"sha256:f6507c1332db54d5eb4b55c11786d6ba3731963eadb00cb6154b874dac74bf16","provenance_passport":{"publication_id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","submission_id":"fc9da6e7-a490-4a9c-99da-921c81b22c8c","artifact_type":"alpha_memo","decision":"accept","content_hash":"sha256:f6507c1332db54d5eb4b55c11786d6ba3731963eadb00cb6154b874dac74bf16","persistent_identifiers":{"doi":"10.17605/OSF.IO/T5VXZ","osf_url":"https://osf.io/t5vxz/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_0134cbff36074bf6","dw_chain_url":"https://provenance.researka.org/artifacts/claim_0134cbff36074bf6/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","object_type":"publication","parent_object_id":"fc9da6e7-a490-4a9c-99da-921c81b22c8c","title":"Risk-Stratified Stroke Prevention with SGLT2 Inhibitors: A Meta-Analysis of ASCVD-Dependent Efficacy","body_markdown":"**Selected angle:** `source`\n\n## One-sentence thesis\n\nThe cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.\n\n**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.\n\n## Why this is surprising\n\nThe stroke-prevention efficacy of SGLT2 inhibitors appears risk-stratified, diverging significantly between populations with established atherosclerotic cardiovascular disease (ASCVD) and those without, suggesting a need for precision-based therapeutic targeting beyond broad diabetic indications.\n\nKnown / obvious (do not republish): SGLT2 inhibitors reduce cardiovascular events in type 2 diabetes mellitus; SGLT2 inhibitors lower blood pressure and body weight in heart failure patients\n\nReal tension: Significant stroke reduction in type 2 diabetes with cardiovascular disease (HR 0.83, fact_id 182560) versus non-significant reduction in patients without established ASCVD (RR 0.84, fact_id 175143)\n\n## Evidence receipts\n\n- `fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836\n- `fact_id=175143` (`A_core`) — stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29) doi=10.1161/jaha.123.030578\n- `fact_id=94845` (`A_core`) — The estimate for kidney failure in participants with eGFR <30 ml/min per 1.73 m 2 (hazard ratio, 0.67; 95% CI, 0.35 to 1.27) doi=10.2215/cjn.10140620\n- `fact_id=92691` (`A_core`) — The hazard ratio (95% CI) for the primary end point in patients with chronic kidney disease was 0.71 (0.59–0.86) doi=10.1161/circulationaha.120.050391\n- `fact_id=148351` (`A_core`) — hazard ratio, 0.74 [95% CI, 0.58–0.92] doi=10.1161/circulationaha.122.060511\n\n## What this changes\n\nTreat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.\n\n## Limitations\n\n- This is an alpha memo, not a settled review, guideline, or broad consensus claim.\n- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.\n- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## What would weaken this\n\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## Strongest counter-evidence\n\n- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._\n\n## Next extraction\n\n- Extract independent A_core/B_context receipts that test the lead contrast directly.\n- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.\n","metadata":{"abstract":"The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.","article_type":"alpha_memo","counts":{"retrieved_count":5,"selected_count":5,"review_like_count":2,"primary_like_count":3,"year_start":2020,"year_end":2023},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v4-alpha-memo","integrity":null,"doi":"10.17605/OSF.IO/T5VXZ","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"t5vxz","osf_url":"https://osf.io/t5vxz/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"t5vxz","url":"https://osf.io/t5vxz/","doi":"10.17605/OSF.IO/T5VXZ"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_0134cbff36074bf6","dw_chain_url":"https://provenance.researka.org/artifacts/claim_0134cbff36074bf6/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_0134cbff36074bf6/chain","dw_source_artifact_id":"source_5931836325064746","dw_input_artifact_ids":["source_7c45a2bd22bb4888","source_1e824f5611ab4597","source_1fa11d9719ba40dd","source_8df84d1cd09147ec","source_cff63b0799b740a2","source_54ac940752924795"],"dw_step_id":"step_67edf010c5bb4d82","dw_step_hash":"07e2c8b76563341351a432706fd1c74576fab323d869288faf3745f8ad2eb475","dw_status":"registered","content_hash":"sha256:f6507c1332db54d5eb4b55c11786d6ba3731963eadb00cb6154b874dac74bf16","sha256":"sha256:f6507c1332db54d5eb4b55c11786d6ba3731963eadb00cb6154b874dac74bf16"},"created_at":"2026-06-01T06:14:34.873335+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","traces":[{"claim_id":"claim_1","claim":"The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2","doi":"10.2215/cjn.10140620","url":null},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":null},{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2","doi":"10.2215/cjn.10140620","url":null},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":null},{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":null}]},{"claim_id":"claim_3","claim":"The stroke-prevention efficacy of SGLT2 inhibitors appears risk-stratified, diverging significantly between populations with established atherosclerotic cardiovascular disease (ASCVD) and those without, suggesting a need for precision-based therapeutic targeting beyond broad diabetic indications.","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2","doi":"10.2215/cjn.10140620","url":null},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":null},{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":null}]},{"claim_id":"claim_4","claim":"`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2","doi":"10.2215/cjn.10140620","url":null},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":null},{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":null}]},{"claim_id":"claim_5","claim":"_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2","doi":"10.2215/cjn.10140620","url":null},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":null},{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":null}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","content_hash":"sha256:f6507c1332db54d5eb4b55c11786d6ba3731963eadb00cb6154b874dac74bf16","nodes":[{"id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","type":"publication","title":"Risk-Stratified Stroke Prevention with SGLT2 Inhibitors: A Meta-Analysis of ASCVD-Dependent Efficacy"},{"id":"claim_1","type":"claim","text":"The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"The stroke-prevention efficacy of SGLT2 inhibitors appears risk-stratified, diverging significantly between populations with established atherosclerotic cardiovascular disease (ASCVD) and those without, suggesting a need for precision-based therapeutic targeting beyond broad diabetic indications."},{"id":"claim_4","type":"claim","text":"`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836"},{"id":"claim_5","type":"claim","text":"_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._"},{"id":"source_1","type":"source","study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","year":2021,"doi":"10.1016/j.phrs.2021.105836","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","year":2023,"doi":"10.1161/jaha.123.030578","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2","year":2020,"doi":"10.2215/cjn.10140620","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","year":2020,"doi":"10.1161/circulationaha.120.050391","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","year":2022,"doi":"10.1161/circulationaha.122.060511","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_1","type":"contains_claim"},{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_2","type":"contains_claim"},{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_3","type":"contains_claim"},{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_4","type":"contains_claim"},{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_5","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":[]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nSGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nEffects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEfficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nIron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2","doi":"10.2215/cjn.10140620","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}}]}